Gilead Sciences financials
$151.28−0.61%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $7.80B | $6.96B | $7.92B | $7.77B | $7.08B | $6.67B | $7.57B | $7.54B | $6.95B | $6.69B | $7.11B | $7.05B |
| Gross profit | $6.22B | $5.51B | $6.30B | $6.20B | $5.58B | $5.13B | $5.99B | $5.97B | $5.41B | $5.13B | $5.02B | $5.49B |
| Gross margin | 79.8% | 79.2% | 79.5% | 79.8% | 78.8% | 76.9% | 79.1% | 79.1% | 77.8% | 76.8% | 70.6% | 77.8% |
| Operating income | -$10.39B | $2.58B | $1.98B | $3.33B | $2.47B | $2.24B | $2.45B | $888.0M | $2.64B | -$4.32B | $1.61B | $2.62B |
| Net income | -$10.50B | $2.02B | $2.18B | $3.05B | $1.96B | $1.31B | $1.78B | $1.25B | $1.61B | -$4.17B | $1.43B | $2.18B |
| Net margin | −134.5% | 29.0% | 27.5% | 39.3% | 27.7% | 19.7% | 23.6% | 16.6% | 23.2% | −62.4% | 20.1% | 30.9% |
| Diluted EPS | $-8.45 | $1.61 | $1.74 | $2.43 | $1.56 | $1.04 | $1.41 | $1.00 | $1.29 | $-3.34 | $1.14 | $1.73 |
| EBITDA | -$7.95B | $3.38B | $3.61B | $4.18B | $3.35B | $3.19B | $3.13B | $3.83B | $3.38B | $2.93B | $2.01B | $3.40B |
| Operating cash flow | $3.57B | $2.54B | $3.33B | $4.11B | $827.0M | $1.76B | $2.98B | $4.31B | $1.32B | $2.22B | $2.17B | $1.75B |
| Free cash flow | $3.43B | $2.43B | $3.12B | $3.96B | $720.0M | $1.65B | $2.83B | $4.17B | $1.20B | $2.11B | $1.95B | $1.63B |
| Diluted shares | 1,243.0M | 1,254.0M | 1,252.0M | 1,254.0M | 1,255.0M | 1,259.0M | 1,268.0M | 1,254.0M | 1,251.0M | 1,247.0M | 1,256.0M | 1,257.0M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $3.18B | $7.63B | $7.56B | $7.33B | $5.14B | $7.93B |
| Short-term investments | $0.00 | $15.0M | $68.0M | $19.0M | $69.0M | $0.00 |
| Total debt | $26.25B | $22.17B | $24.94B | $24.94B | $24.95B | $24.95B |
| Total assets | $49.36B | $56.28B | $59.02B | $58.53B | $55.72B | $56.43B |
| Total liabilities | $37.62B | $32.85B | $36.41B | $37.08B | $36.13B | $37.36B |
| Shareholders' equity | $11.74B | $23.43B | $22.62B | $21.46B | $19.59B | $19.08B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology